Lantheus Holdings, Inc. is a radiopharmaceutical-focused company engaged in delivering science to enable clinicians to find, fight and follow diseases to deliver patient outcomes. The Company classifies its products in three categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships. Radiopharmaceutical Oncology diagnostics and therapeutics help healthcare professionals (HCPs) find, fight and follow cancer, with a focus on prostate cancer. Precision Diagnostic products assist HCPs to find and follow diseases, with a focus on cardiology. Strategic Partnerships focus on enabling precision medicine through the use of biomarker solutions, digital solutions, and radiotherapeutic platforms. Its commercial products include PYLARIFY, DEFINITY, TechneLite, Neuraceq, and others. Its clinical candidates include LNTH-2404, NAV-4694, and PNT2002, among others. The Neuraceq (florbetaben F18 injection) is an F-18 PET imaging agent for Alzheimer’s disease.
公司代码LNTH
公司名称Lantheus Holdings Inc
上市日期Jun 25, 2015
CEOMarkison (Brian A)
员工数量808
证券类型Ordinary Share
年结日Jun 25
公司地址331 Treble Cove Road
城市NORTH BILLERICA
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编01862
电话19786718001
网址https://www.lantheus.com/
公司代码LNTH
上市日期Jun 25, 2015
CEOMarkison (Brian A)